Ewing, NJ (PRNewswire). Celator Pharmaceuticals Inc. announced that VYXEOS (formerly referred to as CPX-351) was recognized with the Nanomedicine Award 2015. This award recognizes projects or products that have been developed using innovative solutions based on nanotechnology.
The Nanomedicine Award 2015 honors the best international nanomedicine innovations in two categories: Best Nanomedicine Early Clinical Stage Project Award and Best Nanomedicine Product or Deal Award.
VYXEOS was selected in the category of the Best Nanomedicine Product or Deal Award. The international program is organized by the European Technology Platform for Nanomedicine (ETPN) together with the consortium Enabling Nanomedicine Translation (ENATRANS). A panel of pharmaceutical industry specialists with global experience in research and development, as well as commercial roles, reviewed the applications and selected VYXEOS.
Dr. Lawrence Mayer, president and chief scientific officer of Celator will accept the award on behalf of the company at BIO-Europe 2015 in Munich, Germany, on November 3. Dr. Mayer was also invited to give a presentation on VYXEOS at the award ceremony.
“We are honored to receive this award as recognition of the impact VYXEOS has made to date, and the potential to become the first product to significantly improve survival of AML patients in over 40 years,” said Dr. Mayer. “VYXEOS represents a validation of the CombiPlex approach, which uses nanoscale carriers to coordinate the delivery of synergistic drug ratios to cancer cells. We are applying our nanotechnology-based approaches to traditional cytotoxics as well as an array of molecularly targeted agents with the hope of increasing their therapeutic benefit and changing the paradigm of combination therapy for cancer.”
The objective of the Nanomedicine Award 2015 is to recognize innovative product developments in nanomedicine and to promote these advances, and the field of nanotechnology, within the international biotechnology and pharmaceutical community. To be selected products must
- address unmet medical needs,
- not be feasible without nanotechnology,
- be distinct from the “standard approaches” such as new chemical entities/small molecules and biologics, and
- have a clearly defined market.
Celator’s Phase 3 study comparing VYXEOS to the current standard of care, known as 7+3, is being conducted in patients with high-risk (secondary) AML. The Phase 3 study completed enrollment in November 2014. Initial data, from a secondary endpoint, showed an improvement in induction response rate in favor of VYXEOS over the 7+3 control arm: 47.7% vs. 33.3%, respectively, for a 43.2% relative improvement. The study’s primary endpoint, overall survival, is expected to be reported in the first quarter of 2016 along with important safety information.
For more information, visit Celator’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
